Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized, Placebo-controlled, Open-label, Three Period Crossover Study to Investigate the Effect of Darolutamide and Enzalutamide on Cerebral Blood Flow in Healthy Male Volunteers

Trial Profile

A Phase I, Randomized, Placebo-controlled, Open-label, Three Period Crossover Study to Investigate the Effect of Darolutamide and Enzalutamide on Cerebral Blood Flow in Healthy Male Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darolutamide (Primary) ; Enzalutamide (Primary)
  • Indications Bladder cancer; Breast cancer; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Salivary gland cancer
  • Focus Pharmacodynamics
  • Sponsors Bayer
  • Most Recent Events

    • 15 Feb 2020 Results assessing significant localized reduction in cerebral blood flow in regions relevant to cognitive function, presented at the 2020 Genitourinary Cancers Symposium
    • 13 Feb 2020 According to Bayers media release, data from this trial will be presented at the 2020 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15, 2020 in San Francisco, California.
    • 05 Dec 2019 Status changed from active, no longer recruiting to completed.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top